NCT06858956尚未招募不适用
Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences0 个研究点目标入组 200 人开始时间: 2025年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 200
- 主要终点
- TTF
研究概览
简要总结
This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced colorectal cancer patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years, male or female.
- •Histologically confirmed advanced colorectal cancer with microsatellite stable (MSS)/proficient mismatch repair (pMMR) status confirmed by immunohistochemistry (IHC) or molecular testing.
- •No restriction on prior immunotherapy or combined anti-angiogenic agents (e.g., bevacizumab or small-molecule TKIs).
- •ECOG performance status of 0-
- •At least one post-treatment efficacy evaluation.
- •Life expectancy ≥3 months.
- •Chidamide treatment duration >3 weeks
排除标准
- •Malignancies in other organs or systems, except for cured basal cell/squamous cell skin cancer or cervical carcinoma.
- •Severe comorbidities that may interfere with efficacy or safety analysis.
- •Conditions deemed unsuitable for study inclusion by the investigator.
结局指标
主要结局
TTF
时间窗: 24 months
次要结局
未报告次要终点
研究者
AIPING ZHOU
Doctor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
相似试验
尚未招募
不适用
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal CancerColorectal Cancer MetastaticNCT06682247Feng Wang200
Unknown
2 期
Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell LymphomaDiffuse Large B-cell LymphomaNCT02733380Henan Cancer Hospital20
尚未招募
3 期
The Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell LymphomaExtranodal Natural Killer T Cell LymphomaNCT06255795Ruijin Hospital142
Unknown
2 期
Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)B-cell Non-Hodgkin's LymphomaNCT03105596Peking University46
已完成
2 期
Chidamide Combined With Zimberelimab in the Treatment of Metastatic Triple-negative Breast Cancer PatientsTriple Negative Breast CancerNCT05632848Sun Yat-sen University47